Literature DB >> 8648267

Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood.

T Bombeli1, M Müller, P W Straub, A Haeberli.   

Abstract

Cyclosporine A (CsA) is supposed to alter the metabolism of vascular endothelial cells, leading to a prothrombotic state. We examined by which mechanism human umbilical vein endothelial cells (HUVECs) treated with CsA would promote coagulation in human plasma and in whole blood. Treatment of HUVECs with CsA at concentrations clinically used led to dose-dependent cell detachment, with the subsequent exposure of the highly procoagulant connective tissue. As determined by scanning electron microscopy, cell counting of detached and adherent cells, and antigenic measurement of collagen exposure, HUVECs treated with 0.4 micrograms/ml CsA (or more) for 4 days exhibited significant amounts of subendothelial areas. On CsA-treated HUVEC monolayers, the clotting time of recalcified citrated platelet-rich plasma (PRP), but not platelet-poor plasma (PPP), was dose-dependently shortened. Likewise, the onset of thrombin generation was significantly earlier. Except at a high concentration of 8.0 micrograms/ml CsA, there was no procoagulant effect when PPP was used. To investigate CsA-treated HUVECs in whole blood, cells were cultivated on globular microcarriers and were incubated with nonanticoagulated whole blood. When untreated cells were used, generation of factor Xa, thrombin, and kallikrein was completely suppressed for 30 minutes. HUVEC beads treated with 0.4 and 0.8 micrograms/ml CsA, however, led to a dose-dependent generation of all three coagulation factors, with peak values at 2.5 to 5 minutes. Extrinsic activation was excluded, since CsA treatment did not induce tissue factor activity in HUVECs. Furthermore, the thrombomodulin activity of HUVECs w as not altered by CsA. In conclusion, treatment of HUVECs with CsA for 4 days at concentrations clinically used leads to the exposure of subendothelial areas that induce activation of the intrinsic coagulation in recalcified PRP and nonanticoagulated whole blood.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648267     DOI: 10.1016/s0022-2143(96)90153-5

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

1.  Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis.

Authors:  Frank C Vandy; Cathy Stabler; Anna M Eliassen; Angela E Hawley; Kenneth E Guire; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2013-04-01

2.  The thrombogenicity of human umbilical vein endothelial cell seeded collagen modules.

Authors:  Alison P McGuigan; Michael V Sefton
Journal:  Biomaterials       Date:  2008-03-05       Impact factor: 12.479

Review 3.  The influence of biomaterials on endothelial cell thrombogenicity.

Authors:  Alison P McGuigan; Michael V Sefton
Journal:  Biomaterials       Date:  2007-02-09       Impact factor: 12.479

4.  Cyclosporin A does not affect platelets in children with idiopathic nephrotic syndrome.

Authors:  Marcin Tkaczyk; Zbigniew Baj; Michał Nowicki
Journal:  Pediatr Nephrol       Date:  2004-10-28       Impact factor: 3.714

Review 5.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 6.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 8.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

9.  Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation.

Authors:  Freeha Arshad; Jelle Adelmeijer; Hans Blokzijl; Aad van den Berg; Robert Porte; Ton Lisman
Journal:  F1000Res       Date:  2014-05-09

10.  Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention.

Authors:  James Yip; David A Bruno; Charlotte Burmeister; Marwan Kazimi; Atsushi Yoshida; Marwan S Abouljoud; Gabriel T Schnickel
Journal:  Transplant Direct       Date:  2016-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.